The World Health Organization (WHO) is hopeful that its Global Diabetes Compact will help to bring the right care to all who need it as well as boosting efforts 14 April 2021
Stock in Provention Bio fell 35% ahead of trading on Friday, after the firm reported a regulatory setback related to its novel diabetes med teplizumab. 9 April 2021
The odds for and against betting on Provention Bio’s teplizumab, which is being studied in the prevention of type 1 diabetes (T1D) among at-risk patients, have 22 March 2021
Shares in diabetes giant Novo Nordisk fell back 4% on Thursday, after its blockbuster Ozempic (semaglutide) was outshone in a head-to-head study. 5 March 2021
German science and technology company Merck KGaA has reported impressive sales and earnings figures in its latest quarterly and full-year 2020 financial results 4 March 2021
Agreement has been reached for Takeda to transfer the assets, marketing rights and, eventually, marketing authorization associated with a portfolio of diabetes 26 February 2021
New Phase III data from Novo Nordisk show that a once-weekly 2.4mg dose of semaglutide can have a dramatic impact on weight loss, raising the prospect that the 11 February 2021
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.